Development-stage medical device company Cerebain Biotech today announced it is planning to begin development of its medical device designed for the treatment of Alzheimer’s and Dementia.
The company is developing a minimally invasive implantable device designed for omentum stimulation, which the company said has a “clinically observable, positive impact” on cognitive function related to dementias and Alzheimer’s disease.
The device under development can be adjusted non-invasively to account for a “range of factors” which include frequency, strength of stimulation and location, according to the company’s website.
“We would like to offer a heartfelt thank you to each and every shareholder: past, current, and future for your unwavering support of our company and for also taking the time to read this important shareholder update. We are extremely excited to continue to move forward with our development plan and to do everything in our power to eradicate Alzheimer’s disease while adding to shareholder value,” Cerebain prez Eric Clemons said in a press release.
Cerebain said it recently relocated its headquarters from Dallas, Texas to Costa Mesa, Calif. as it seeks FDA approval for the device. The company said it plans to allocate resources for pursuing FDA approval over the coming months.
The company said it also inked a memorandum of understanding with the department of neurodegenerative diseases at Poland’s Mossakowski Medical Research Centre to allow for testing of the device once development is completed.
The post Cerebain Biotech set to begin development on medical device for Alzheimer’s appeared first on MassDevice.
from MassDevice http://ift.tt/2cTS5o5
Cap comentari:
Publica un comentari a l'entrada